The National Health Service has a new drugs deal
Patients and pharma firms will be relieved. But it is not yet clear who benefits most
TWO DAYS, TWO deals for the National Health Service (NHS). On November 21st the NHS announced that it had awarded a contract worth up to £330m ($414m) to Palantir, a controversial American firm, to help it join up patient data in England and thereby, it hopes, to improve care for millions. This followed the announcement a day earlier of a new drugs deal, after months of wrangling with the British government, which funds the service, and the Association of the British Pharmaceutical Industry (ABPI), representing drugmakers.
Explore more
This article appeared in the Britain section of the print edition under the headline “Drug dealing”
Britain November 25th 2023
- Britain’s chancellor offers tax cuts and fiscal trickery
- Jeremy Hunt wants to improve Britain’s public-sector productivity
- The government tries to unlock growth capital for British firms
- The world’s first pathway for individually designed drugs
- The National Health Service has a new drugs deal
- Is Britain’s plan to send asylum-seekers to Rwanda salvageable?
- Britain’s native farm animals can be rarer than giant pandas
- What kind of legacy does Rishi Sunak want to leave behind?
From the November 25th 2023 edition
Discover stories from this section and more in the list of contents
Explore the editionMore from Britain
The rise of the Net-Zero Dad
Middle-aged men care less about the problem. But they love the solution
Backing Heathrow expansion suggests Labour is serious about growth
It is the surest sign yet that the government is up for the fight
What the rise of bubble tea says about British high streets
A sugar rush from foreign students
Why Britain has fallen behind on road safety
More than 1,600 people still die each year in road collisions
Britain’s brokers are diversifying and becoming less British
London’s depleted stockmarket is forcing them to change